We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Groundbreaking Ultrasound-Based Software Aids Physicians Performing Liver Tumor Ablations

By MedImaging International staff writers
Posted on 10 Jan 2024
Print article
Image: 3D simulation of percutaneous liver tumor ablation (Photo courtesy of Techsomed)
Image: 3D simulation of percutaneous liver tumor ablation (Photo courtesy of Techsomed)

Ablation therapy, a minimally invasive treatment that employs extreme temperatures, presently lacks the tools to predict the impact of ablation based on ultrasound. Imaging plays a vital role in tumor ablation. Although ultrasound serves as a cost-efficient and patient-friendly option for real-time visualization, there exists potential for improving visualization and continuously monitoring the response of the ablation tissue. Now, a groundbreaking software can aid physicians conducting liver tumor ablations by offering visualization of the ablated area based on standard real-time ultrasound imaging.

BioTraceIO from Techsomed Medical Technologies (Rehovot, Israel) is an ultrasound-based software for tissue response prediction in liver tumor ablation that employs a unique computational algorithm to analyze ultrasound images captured during liver ablation treatment. It offers real-time visualization and tracking of the Reference Ablation Zone (RAZ), utilizing technical data from the ablation device manufacturers. After the ablation procedure, it generates a visual representation of the estimated ablation zone. This visualization is expected to match the results seen in a 24-hour contrast-enhanced CT (CECT) scan. This feature is particularly valuable, given that studies indicate a notable increase in the volume of the ablation zone 24 hours post-procedure, which is when it typically stabilizes.

The efficacy of BioTraceIO has been thoroughly tested and confirmed through a pivotal multi-center study in the USA, involving 50 patients. The study's findings show that BioTraceIO's predictions are more accurate than immediate post-procedure CECT scans in estimating the ablation zone as observed in 24-hour CECT. This is significant because the software can accurately forecast the size and shape of the ablation zone based on ultrasound images alone that correlate with CT information. The FDA has granted De Novo clearance for BioTraceIO which complements Techsomed's VisAble.IO, an AI-powered ablation treatment planning and confirmation product. The integrated solution provides a comprehensive image-guided ablation visualization framework for eliminating guesswork typically associated with thermal ablation therapy.

"Techsomed has taken a major step towards making our vision for image-guided ablation therapy a reality," said Yossi Abu, Techsomed's CEO and founder. "The FDA's De Novo clearance is game-changing as we gear up to commercialize both BioTrace.IO and VisAble.IO across multiple market segments in the USA. We are genuinely excited to be able to offer physicians smart solutions that bring a new level of precision to ablation therapy.”

New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
Transducer Covers
Surgi Intraoperative Covers
New
X-ray Diagnostic System
FDX Visionary-A
New
Mobile Barrier
Tilted Mobile Leaded Barrier

Print article

Channels

MRI

view channel
Image: Late gadolinium enhancement distinguishes which hypertrophic cardiomyopathy patients will benefit from urgent interventions (Photo courtesy of 123RF)

Enhanced Cardiovascular MRI Predicts Heart Risk in Children with Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiovascular disorder and a leading cause of sudden cardiac death in young people, with a yearly mortality rate of 1%. However, 10% to... Read more

Nuclear Medicine

view channel
Image: Example of AI analysis of PET/CT images (Photo courtesy of Academic Radiology; DOI: 10.1016/j.acra.2024.08.043)

AI Analysis of PET/CT Images Predicts Side Effects of Immunotherapy in Lung Cancer

Immunotherapy has significantly advanced the treatment of primary lung cancer, but it can sometimes lead to a severe side effect known as interstitial lung disease. This condition is characterized by lung... Read more

General/Advanced Imaging

view channel
Image: AI-enabled analysis of images meant to catch one disease can reveal others (Photo courtesy of 123RF)

AI Tool Offers Opportunistic Screening for Heart Disease Using Repurposed CT Scans

In the field of medical imaging, the term "opportunistic screening" refers to the repurposing of existing medical images by radiologists to diagnose illnesses beyond what the scan was originally meant to find.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.